The goal is control of copper uptake
The label explains that zinc promotes intestinal metallothionein, a protein that binds copper and limits its transfer into the blood. Bound copper is lost as intestinal cells are shed. This mechanism is relevant to the abnormal copper accumulation of Wilson disease, not a reason for everyone to reduce copper absorption. [1]
Treatment requires continuing monitoring
The indication is maintenance after initial chelation, and the label includes monitoring of copper control. It also warns that prolonged zinc acetate treatment can cause copper deficiency, with blood-cell and neurological complications. A nutrient used therapeutically can therefore require substantial supervision. [1]
Do not substitute by the front-label milligrams
Imagine someone replaces a prescribed Galzin regimen with a retail zinc product because both labels mention zinc. The formulation, elemental amount, timing and monitoring plan need review by the treating team. Do not start, stop or substitute Wilson-disease therapy based only on a general supplement comparison. [1][2]
| Name or claim | What it means |
|---|---|
| Galzin indication | Wilson-disease maintenance treatment |
| Copper absorption reduction | A therapeutic effect requiring monitoring |
| Retail zinc bottle | Not an automatic prescription substitute |
Sources for this article
- DailyMed - GALZIN- zinc acetate capsule, gelatin coated
Source consulted: 2026-09-20. This is a reference resource, not a claim that we conducted the studies or tested a product. - Zinc - Health Professional Fact Sheet
Source consulted: 2026-09-20. This is a reference resource, not a claim that we conducted the studies or tested a product.